本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SUBANG JAYA, Malaysia, June 23, 2025 /PRNewswire/ -- Taylor's University has secured the 253rd position in the latest QS World University Rankings 2026, reinforcing its status as the top-ranked non-government-linked private university in Southeast Asia. This achievement marks Taylor's consistent presence in the top 1% of universities worldwide. Taylor’s continued strong performance in the QS rankings gives rise to a bold 10-year strategic plan to transform the Malaysian private university into a future-ready institution of global stature Taylor's strong global standing is underscored by its 92nd rankingfor employer reputation, making it the top private institution in Southeast Asia for this indicator. This aligns with findings from the Ministry of Higher Education's (MOHE) 2024 Graduate Tracer Study, which reports a 99.5% graduate employability rate for Taylor's—well above the national average of 92.5%. This indicator highlight that Taylor's graduates are highly sought after for their industry-relevant skills and readiness to contribute effectively in the workforce. Equally important is Taylor's commitment to nurturing a globally diverse student community, as demonstrated by its 34th ranking for international student population, reflecting the university's success in attracting and supporting a vibrant, globally minded student body. "As a modern progressive institution, we are committed to building world-class education driven by innovation and real-world impact. We are growing our student community, investing in staff, and advancing capabilities to address global challenges through industry partnerships, AI-powered learning, and purpose-driven innovation. In line with our aspirations to facilitate nation-building efforts, we aim to empower students to reach their full potential, align research with national priorities, and foster local and global partnerships that drive meaningful change. In doing so, we support Malaysia's efforts to develop talent and strengthen its position as an education hub in the region," said Professor Barry Winn, Vice-Chancellor and President of Taylor's University. Taylor's University is committed to advancing purpose-driven education, reinforcing academic integrity across borders amid the rise of transnational education, and reimagining curricula to reflect diverse, globally relevant, and locally grounded perspectives. At the same time, the university is redefining faculty roles—empowering educators as mentors, innovators, and change agents—to deliver dynamic hybrid learning experiences that equip graduates to navigate the complexities of the future. For more information about Taylor's University and its programmes, please visit the website.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 23, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") to advance BCMAxCD3 bispecific T-cell engagers for the treatment of autoimmune diseases. Under the terms of the agreement, Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan). In return, Harbour BioMed will receive a total of $47 million in upfront and near-term payments. The company is also eligible for additional payments of up to $623 million upon the achievement of specified development and commercial milestones, as well as tiered royalties on future net sales. This strategic collaboration establishes a foundation for potential future partnerships between the two companies in the T-cell engager area. "We are delighted to collaborate with Otsuka, a global healthcare leader renowned for its innovative approach to addressing unmet medical needs," said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "This collaboration underscores the strength of Harbour BioMed's proprietary Harbour Mice® and HBICE® technology platforms, which enable the rapid development of fully human bispecific antibodies with optimized safety and efficacy profiles. By leveraging our unique capabilities, we are well-positioned to advance next-generation biotherapeutics that can make a meaningful difference in patients' lives worldwide." Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical, noted, "Otsuka is expanding our development pipeline in the autoimmune disease field by leveraging the antibody drug platform of our subsidiary Visterra, and the small molecule drug discovery platform of our subsidiary Jnana. HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialized autoimmune diseases and thereby benefit patients." About HBM7020 HBM7020 is a BCMAxCD3 bispecific antibody generated using Harbour BioMed's fully human HBICE® bispecific technology and Harbour Mice® platform. It is designed to crosslink target cells and T cells by binding to BCMA and CD3 on the cell surface, leading to potent T cell activation and targeted cell elimination. By incorporating dual anti-BCMA binding sites for enhanced cell targeting and monovalent-optimized CD3 activity to minimize cytokine release syndrome (CRS), HBM7020 has demonstrated potent cytotoxicity with broad therapeutic potential in both immunological and oncological diseases. In August 2023, HBM7020 obtained IND clearance from the National Medical Products Administration (NMPA) to commence a Phase I trial for cancer in China. About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com. About Otsuka Pharmaceutical Co., Ltd. Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit www.otsuka.co.jp/en/
上海 2025年6月23日 /美通社/ -- 雲頂新耀（HKEX: 1952.HK），一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈《依拉環素體外藥物敏感性試驗規範（2025）》(以下簡稱「規範」)已在《中華檢驗醫學雜誌》正式發表。規範旨在為微生物學檢驗人員和臨床醫師規範開展依拉環素體外藥敏試驗和結果解讀提供參考，以期「有據可依」地指導臨床合理用藥；同時也有助於促進臨床微生物學實驗室對依拉環素藥敏試驗操作方法的規範性和結果報告的準確性，「有依可靠」地支持依拉環素應對臨床多重耐藥菌感染和複雜感染的挑戰。 該規範由國家衛生健康委臨床抗微生物藥物敏感性折點研究和標準制定專家委員會（以下簡稱「國家藥敏專委會」，ChinaCAST）、中國醫院協會臨床微生物實驗室專業委員會、歐洲臨床微生物與感染病學會藥敏委員會華人藥敏試驗委員會共同制定。 依拉環素是全球首個氟環素類抗菌藥物，具有抗菌譜廣、抗菌活性強、臨床療效確切、安全性良好等特點，已廣泛應用於多重耐藥菌及複雜感染的治療，是臨床治療的新選擇。規範從三個維度全面梳理了依拉環素的抗菌作用機制及特點、藥敏試驗和依拉環素藥敏試驗結果判讀臨床折點，重點強調依拉環素藥敏試驗操作的規範性和結果判讀的準確性等，系統覆蓋微量肉湯稀釋法、梯度擴散法（MTS/Etest）和紙片擴散法等主流檢測方法，並明確試驗的質控範圍與判讀標準。 此次發佈的規範與2024年ChinaCAST發佈的依拉環素中國臨床折點相輔相成，形成「標尺合一」的完整技術體系。該臨床折點在充分參考歐洲藥敏試驗委員會（EUCAST）、美國食品藥品監督管理局（FDA）等國際權威標準的基礎上，結合中國及全球其他區域最新的體外和臨床研究數據制定，針對金黃色葡萄球菌、糞腸球菌、屎腸球菌、咽峽炎鏈球菌群、脆弱擬桿菌、鮑曼不動桿菌、肺炎克雷伯菌和大腸埃希菌等多種臨床常見病原體設定了具體的MIC及抑菌圈直徑判讀標準。依拉環素是國家藥敏專委會成立以來首個且目前唯一通過審評，建立中國臨床折點的抗菌藥物，具有重要的里程碑意義。 歐洲藥敏試驗委員會華人藥敏試驗委員會第一屆主任委員，北京協和醫院徐英春教授表示：「《依拉環素體外藥物敏感性試驗規範（2025）》在《中華檢驗醫學雜誌》的正式發表，是我國抗菌藥物敏感試驗標準從引進國際標準參考走向自主制定的關鍵跨越。依拉環素在我國藥監局批准上市後，中國臨床折點的建立，有助於促進臨床微生物實驗室對於依拉環素藥敏操作方法的規範性和結果報告的準確性，達到『標尺一體』。 這也有助於指導臨床合理應用新型抗菌藥，讓更多耐藥菌感染患者獲得救治機會以及更好的預後，同時對遏制細菌耐藥具有重要的意義。此前由國家衛生健康委抗菌藥物臨床應用與耐藥評價專家委員會發起並主辦的依拉環素臨床應用綜合評價項目終期報告，驗證了依拉環素抗菌譜廣、抗菌活性強、治療多重耐藥菌所致感染的臨床療效顯著，不良事件發生率低，為臨床積極應對多重耐藥菌感染威脅提供了有力武器。」 雲頂新耀首席執行官羅永慶表示：「目前，抗微生物藥物耐藥性已被WHO列為全球十大公共衛生威脅之一，到2050年，每年可能導致1000萬人死亡，超過癌症的死亡人數，成為致死的主要原因，給人類健康帶來沉重的疾病負擔。《依拉環素體外藥物敏感性試驗規範（2025）》的正式發佈，是依拉環素（依嘉®）走向標準化應用的重要一步。該規範為臨床微生物室提供規範的、標準的操作路徑和實踐指南，有助於提升藥敏檢測開展的規範性和結果報告的準確性，從而讓更多面臨耐藥菌感染威脅的患者獲益於依拉環素的應用。同時，這也為依拉環素在複雜感染治療中的臨床合理應用提供保障，奠定其進一步納入臨床路徑與診療指南、充分發揮遏制耐藥菌感染價值的堅實基礎。作為全球首個且唯一的全新一類的抗菌藥物—氟環素類，依拉環素已獲得國內外多個治療指南/共識的推薦，並在2024年被WHO列入《醫學上重要的抗微生物藥物》清單。」 2024年11月，國家衛生健康委抗菌藥物臨床應用與耐藥評價專家委員會發起並主辦的「依拉環素臨床應用綜合評價項目」總結會在北京舉行，並發佈了項目終期報告。依拉環素臨床應用綜合評價項目自2023年9月23日啟動，於2024年11月完成項目數據收集。項目共採集病例3369例，來自全國231家醫院的839位醫生。終期報告顯示，經依拉環素治療3天時的整體有效率為91.1%，治療結束時的總治療有效率為90.1%。依拉環素在治療來自ICU、血液科、移植科、呼吸科等多個科室的感染患者，尤其對於碳青霉烯耐藥的鮑曼不動桿菌、肺炎克雷伯菌等多種病原體導致的肺部感染患者中，顯示出良好的療效和安全性。 2024年3月，世界衛生組織（WHO）在其更新的《醫學上重要的抗微生物藥物》（Medically Important Antimicrobials, MIA）清單中，並基於氟環素對四環素側鏈的全新結構改造及其對耐藥機制的顯著突破，將氟環素單獨劃分為一個新的抗菌類別，其中依拉環素為該類別中的唯一代表藥物。 依嘉®於2023年3月獲得中國國家藥品監督管理局（NMPA）批准，並於同年7月在中國成功上市，適應症涵蓋臨床常見的革蘭陽性菌、革蘭陰性菌、厭氧菌及包括耐藥肺炎支原體在內的非典型病原體。依嘉®已被納入2023年版中國《耐碳青霉烯革蘭陰性菌（CRO）感染的診療與防控指南》等多項權威指南和專家共識。 關於依嘉® （依拉環素） 依嘉®（依拉環素）是全球首個氟環素類抗菌藥物，用於治療包括臨床常見多重耐藥菌在內的革蘭陰性菌、革蘭陽性菌、厭氧菌等所引起的感染。依嘉®目前已在美國、歐盟、英國、新加坡、中國大陸、中國香港和中國台灣地區被批准用於治療複雜性腹腔內感染（cIAI）。依嘉®是雲頂新耀從Tetraphase製藥公司（為Innoviva, Inc.的全資子公司）授權引進。 關於雲頂新耀 雲頂新耀是一家專注於創新藥和疫苗研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業從事過高質量研發、臨床開發、藥政事務、化學製造與控制（CMC）、業務發展和商業化運營，擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合，公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多信息，請訪問公司網站：www.everestmedicines.com。 前瞻性聲明 本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。
SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) (hereinafter referred to as the "Specifications") have been officially published in the Chinese Journal of Laboratory Medicine. The Specifications aim to offer standardized protocols for microbiology laboratory professionals and clinicians to conduct and interpret in vitro antimicrobial susceptibility testing (AST) of eravacycline. It supports rational clinical use of eravacycline based on standardized evidence and enhances the accuracy and consistency of susceptibility testing results across clinical microbiology laboratories, thereby better addressing the challenges of treating multidrug-resistant (MDR) and complicated infections. The Specifications were jointly developed by the Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (hereinafter referred to as the "ChinaCAST"), the Clinical Microbiology Laboratory Specialized Committee of Chinese Hospital Association, and the Chinese Committee on Antimicrobial Susceptibility Testing, affiliated to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). As a novel fluorocycline antimicrobial, eravacycline possesses broad-spectrum antibacterial coverage, potent activity, and favorable safety and efficacy in comparison to a carbapenem in the registrational trials. It is widely applied in the treatment of multidrug-resistant (MDR) pathogens and complicated intra-abdominal infections. The Specifications comprehensively outline three key areas: the antimicrobial mechanism and features of eravacycline, the AST methods, and clinical breakpoints for result interpretation. It emphasizes the standardization of procedures and accuracy of interpretation, and covers leading AST methodologies including broth microdilution, gradient diffusion (MTS/Etest), and disk diffusion methods, along with defined quality control parameters and interpretive criteria. This publication complements the China clinical breakpoints for eravacycline released by ChinaCAST in 2024, creating a unified technical framework that integrates breakpoint definitions with standardized testing protocols. These breakpoints were established based on thorough evaluation of international standards, including those from EUCAST and the FDA, and were further informed by the latest in vitro and clinical research data from China and other global regions. The clinical breakpoints include minimum inhibitory concentration (MIC) and zone diameter criteria for common pathogens such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcusanginosus group, Bacteroides fragilis, Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. Eravacycline is the first and currently the only antimicrobial agent to have been granted China-specific clinical breakpoints following formal expert evaluation by ChinaCAST. This publication and the granting of China's clinical breakpoints for eravacycline mark a milestone in establishing China's national antimicrobial susceptibility standards. "The publication of Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) in the Chinese Journal of Laboratory Medicine marks a pivotal transition for China's antimicrobial susceptibility testing standards from adopting international references to independent formulation, " said Professor Yingchun Xu, The inaugural chairman of the Chinese Committee of the EUCAST (European Committee on Antimicrobial Susceptibility Testing) and Chair of the Department of Clinical Laboratory Diagnostics, Peking Union Medical College. "The establishment of clinical breakpoints for eravacycline, a novel drug approved by China's NMPA, will ensure procedural standardization and result accuracy of Antimicrobial Susceptibility Testing of eravacycline in clinical laboratories, achieving 'standardization and uniformity.' This advancement will guide rational clinical use of new antimicrobial agents, expand treatment options, and improve patient prognoses, while significantly contributing to Combating Bacterial Resistance. According to the final report of the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline.", released by the National Health Commission of China, the efficacy of eravacycline in treating drug-resistant bacterial infections, especially in ICU and hematology applications, has brought significant clinical benefits to patients." "Currently, antimicrobial resistance has been listed by the World Health Organization as one of the top ten public health threats globally, bringing a heavy disease burden to human health. The official publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) marks a critical step toward the standardized clinical application of XERAVA® (eravacycline)." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "The Specifications provides clinical microbiology laboratories with a standardized procedural pathways and evidence-based practice guideline, helping to enhance the consistency of susceptibility testing procedures and the accuracy of result reporting. This will enable more patients threatened by drug-resistant infections to benefit from eravacycline-based therapies. Furthermore, it establishes a robust foundation for ensuring the rational clinical use of XERAVA® in the treatment of complicated infections thereby facilitating its inclusion in clinical pathways and treatment guidelines to maximize its value in combating resistant bacterial infections. As the first and only flourocycline antibiotic, eravacycline has been recommended by multiple domestic and international treatment guidelines. It is also included in the WHO's updated 2024 list of antimicrobials of high medical importance." The Comprehensive Evaluation Project, led by the National Health Commission's Expert Committee on Clinical Use of Antimicrobials and Evaluation of Antimicrobial Resistance, began in September 2023, and the data analysis was completed in November 2024. A total of 3,369 cases from 839 physicians across 231 hospitals nationwide were collected. Six final reports were released, including one overall project data analysis report and five specialty reports. The final report showed a 91.1% overall efficacy rate after 3 days of eravacycline treatment, and the 90.1% at the end of treatment. In March 2024, the World Health Organization (WHO) updated its list of "Medically Important Antimicrobials" (MIA). Based on the novel modification of the tetracycline side chain, which significantly changes its resistance mechanisms, the WHO categorized fluorocycline as a new class of antimicrobial drugs, with eravacycline as the only drug in this class. XERAVA® was approved by the National Medical Products Administration (NMPA) of China in March 2023 and commercially launched in July. Its antibacterial spectrum covers a wide range of clinically relevant bacteria, including Gram-negative, Gram-positive, anaerobic bacteria. Eravacycline has been included in several clinical guidelines and expert consensuses, such as the 2023 edition of China's "Diagnosis, Treatment, and Prevention Guidelines for Carbapenem-Resistant Gram-Negative Organisms (CRO) Infections". About XERAVA® (eravacycline) XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative, Gram-positive and anaerobic pathogens, including those pathogens that have acquired multidrug resistance (MDR) and are prevalent in China. XERAVA® is currently approved for the treatment of complicated intra-abdominal infections (cIAI) in the US, EU, UK, Singapore, mainland China, Hong Kong, and Taiwan. XERAVA® was licensed to Everest by Tetraphase Pharmaceuticals, Inc., an affiliate of Innoviva Specialty Therapeutics, Inc. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
MELBOURNE, Australia, June 23, 2025 /PRNewswire/ -- SSAB has taken decisive action against two Indian companies selling counterfeit steel. The unauthorised products, labelled with the Hardox® trademark, exhibited severe quality issues, posing risks to buyers who believed they were purchasing genuine Hardox® wear plate. Following a recent investigation and lawsuit in India, two companies based in the Mumbai area admitted to trademark infringement and passing off, both serious violations of SSAB's intellectual property rights. The companies not only paid exemplary damages but also faced a permanent injunction in the lawsuit and were directed to cease all use of the infringing marks. Additionally, they issued unconditional public apologies to SSAB. Protecting customers from counterfeit products in Australia Only the Swedish steel manufacturer SSAB produces genuine Hardox® wear plate, and Hardox® wear plate is only available from SSAB and from SSAB-certified suppliers. Each month, SSAB successfully removes hundreds of website links, online marketplace advertisements and social media pages based in India and China, offering counterfeit products or falsely claiming to stock genuine Hardox® wear plate for export to Australia and other parts of the world, often at very low prices. Hardox® wear plate is a premium, high-quality product known for its exceptional hardness and toughness. Its guaranteed properties deliver outstanding performance, making it a market leader in wear resistance—and naturally, not a low-cost option. Therefore, a simple guiding principle is that if a deal seems too good to be true, it likely involves counterfeit steel. SSAB strongly encourages buyers to purchase Hardox® wear plate only from SSAB-certified suppliers. Where to buy genuine Hardox® wear plate and wear parts in Australia SSAB maintains its own sales network. To ensure product authenticity, Hardox® wear plate should only be purchased through SSAB's own local stocks in Australia, SSAB's mills and through our authorised Hardox® Wearparts Centers in the Pacific region. https://www.hardoxwearparts.com/find-center/ Reporting counterfeit steel At SSAB, we are committed to ensuring that customers receive only high-quality, genuine Hardox® wear plate they can trust. If you encounter branded steel that you suspect is not genuine Hardox® wear plate, we urge you to contact your local SSAB sales team immediately. The risks of buying from unauthorized sources Buying from unauthorised sources may result in: Operational setbacks – Counterfeit steel often has lower quality and therefore lower durability, leading to frequent repairs, replacements and increased maintenance costs. Health and safety risks – Inferior materials may compromise structural integrity, increasing the risk of failures and accidents. Legal repercussions – The use of counterfeit steel could lead to litigation, fines or other regulatory consequences. Environmental impact – Counterfeit production methods often neglect sustainability standards, leading to increased contamination and waste. SSAB is a Nordic and US-based steel company that builds a stronger, lighter and more sustainable world through value added steel products and services. Working with our partners, SSAB has developed SSAB Fossil-free™ steel and plans to reinvent the value chain from the mine to the end customer, largely eliminating carbon dioxide emissions from our own operations. SSAB Zero™, a largely carbon emission-free steel based on recycled steel, further strengthens SSAB's leadership position and our comprehensive, sustainable offering independent of the raw material. SSAB has employees in over 50 countries and production facilities in Sweden, Finland and the US. SSAB is listed on Nasdaq Stockholm and has a secondary listing on Nasdaq Helsinki. Join us on our journey! www.ssab.com, Facebook, Instagram, LinkedIn, X and YouTube.
赫爾辛基 2025年6月23日 /美通社/ -- 今天在 2025 年 European Academy of Neurology (EAN) Congress 上發表的最新研究顯示，經常做惡夢會顯著加速生物老化，並使過早死亡的風險增加三倍以上。這項研究首次顯示，即使考慮到其他健康問題，惡夢本身也能獨立預測更快的生理老化和更早的死亡率。 本研究由英國癡呆症研究所 (UK Dementia Research Institute) 和倫敦帝國學院 (Imperial College London) 的 Abidemi Otaiku 博士領導，分析了六個長期人口群組中 2,429 名 8 至 10 歲兒童和 183,012 名 26 至 86 歲成人的資料。 成人的惡夢頻率是在研究開始時自我報告的，參與者的追蹤期長達 19 年。對於兒童而言，噩夢頻率是由其父母在研究開始時報告的。 結果顯示，與很少或從未做惡夢的人相比，每週做惡夢的成年人早逝（70 歲前）的機會高出三倍以上。惡夢較頻仍的兒童和成人，生物老化速度也相應較快，約佔死亡風險提高的 40%。 值得注意的是，研究發現每星期做惡夢，比其他已確立的風險因素如吸煙、肥胖、飲食不佳和體能活動少，更能預測過早死亡。 「我們睡著的大腦無法區分夢與現實，」Otaiku 博士解釋說：「這就是何解惡夢經常讓我們驚醒，大汗淋漓、喘不過氣、心跳加速，因為我們的戰鬥或逃跑反應被觸發。這種壓力反應，甚至比我們在醒時經歷的任何事情更激烈。」 他繼續說：「惡夢會導致皮質醇的長期升高，這是一種與細胞加速老化密切相關的壓力荷爾蒙。對於經常遇到惡夢的人而言，這種壓力累積可能會顯著影響老化過程。此外，惡夢會擾亂睡眠品質和持續時間，損害人體重要的隔夜細胞恢復和修復功能。慢性壓力和睡眠中斷的結合影響，可能會促進我們細胞和身體的加速老化。」 頻繁做惡夢與加速老化之間的關係在所有年齡層、性別、種族和心理健康狀態中都保持一致，表明惡夢具有普遍影響。與很少做惡夢或不做惡夢相比，即使每月都做惡夢也與老化速度加快和死亡率增加有關，減少全體人口做惡夢頻率的重要性不言而喻。
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
